



Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

Yulan Qi^{1,2} · Kathleen McKeever¹ · Julie Taylor¹ · Christine Haller¹ · Wenjie Song^{1,3} · Simon A. Jones⁴ · Jack Shi¹

Published online: 4 December 2018
© The Author(s) 2019

Correction to: *Clinical Pharmacokinetics*
<https://doi.org/10.1007/s40262-018-0721-y>

The original article was corrected.

Introduction section, para 3, lines 2–4 which previously read:

In an open-label, phase I/II, dose-finding trial (ClinicalTrials.gov identifier: NCT02418455),...

should read:

In an open-label, phase I/II, dose-finding trial (ClinicalTrials.gov identifier: NCT01856218),...

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40262-018-0721-y>.

✉ Yulan Qi
yulan.qi@gmail.com

- ¹ Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA 94949, USA
- ² Present Address: BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA 94949, USA
- ³ Present Address: Ascendis Pharmaceutical Inc., 500 Emerson St., Palo Alto 94301, USA
- ⁴ Willink Unit, Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester and Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK